Exor faces challenges with Stellantis and CNH, but Ferrari's strong performance bolsters its financial stability. Exor's strategic shift towards luxury brands and healthcare indicates a potential move ...
Philips resolved the Respironics litigation, settling for $1.1 billion. And Exor decided to boost its stake in the company. Supportive shareholders' remuneration is linked to Exor's portfolio results, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback